Cellectar Biosciences, Inc. (CLRB), a clinical biopharmaceutical company, is at the forefront of discovering, developing, and commercializing drugs for cancer treatment. Its leading drug candidate, CLR 131 (iopofosine I-131), is undergoing Phase 2 clinical studies for B-cell malignancies, relapsed or refractory (r/r) Waldenstrom's macroglobulinemia, r/r multiple myeloma (MM), and r/r non-Hodgkin's lymphoma. Additionally, CLR 131 is in Phase 1 clinical studies for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors, as well as for r/r head and neck cancer.
The company is also advancing CLR 1900, a phospholipid drug conjugate (PDC) chemotherapeutic program aimed at treating solid tumors, which is currently in the preclinical development stage. Cellectar Biosciences has established collaborations with Orano Med for the development of the CLR 12120 Series and with LegoChemBio, further expanding its research and development capabilities.
Founded in 2002 and based in Florham Park, New Jersey, Cellectar Biosciences is dedicated to improving the lives of cancer patients through innovative treatments. With a market cap of 11.65M and a focus on biotechnology within the healthcare sector, the company continues to explore new avenues in cancer therapy, aiming to bring hope and effective treatments to patients worldwide.
